Search

Adalimumab (ADA) is a recombinant human monoclonal antibody indicated for the treatment of psoriasis that specifically inhibits tumor necrosis factor. Until recently we only had the presentation of 40 mg of ADA, being the standard dose in adults an initial administration of 80 mg, followed by 40 mg every 2 weeks. Newly the presentation of 80 mg of ADA has been commercialized, allowing the administration of the standard dose or a higher dose, with fewer injections. In this study, we retrospectively studied 11 patients with psoriasis who have received treatment with the presentation of 80 mg of ADA in two dermatology departments of two hospitals in Spain since its commercialization until June 2019. At the end of the study, an improvement in the mean final Psoriasis Area Severity Index (PASI) of all patients was observed, without any patient presenting any adverse effects. This study shows the efficacy and safety of 80 mg of ADA in a sample of 11 patients with psoriasis.

Nino varon de siete anos con prurito del cuero cabelludo de reciente aparicion tras volver de un campamento de verano. La madre traia la almohada del nino, manchada con multiples hemorragias puntiformes (fig. 1). Estos hallazgos y la clinica relatada orientaron el diagnostico de Pediculosis capitis. La exploracion minuciosa del cabello de este paciente y el estudio del cabello mediante peinado con el pelo mojado demostro tanto la presencia de liendres eclosionadas como liendres con parasitos vivos en su interior; el diagnostico de infestacion activa se establecio al observar los parasitos adulto, como se ve en esta imagen de microscopia optica (fig. 2).